Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties and multi-target mechanisms of action.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $4.5MThe company’s own SEC segment disclosure.
- Royalty$4.4M98%
- License$100.0K2%
Xencor, Inc. (XNCR) reported revenue of $4.5M in Q1 2026 (quarter ended March 31, 2026), down 86% from the same quarter a year earlier. That came with net loss of $129M. For the full year FY2025, revenue was $126M (+14% year on year) and net income −$92M. Its largest product in 2026-Q1 was Royalty at $4.4M, 98% of the disclosed total, just ahead of License at 2.2%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
The closest names by size in the same industry